Business Wire

Joint Tsinghua-Liverpool Research Team Discover New Charge Storage Mechanism

16.8.2021 12:00:00 EEST | Business Wire | Press release

Share

Due to their high energy density and low cost, metal-air batteries are one of the most promising power sources of the future. A joint Tsinghua-Liverpool research team has recently developed a new charge storage mechanism that allows rechargeability within calcium-air batteries - a major step forward in battery technology.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210816005031/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Lu in Prof Hu’s lab where he set up experiments to cross compare results obtained at NTHU and at UoL.(Photo: National Tsing Hua University)

This discovery has been published in Chemical Science. The lead author of the paper, Yi-Ting Lu, is a joint doctoral student at Tsinghua and Liverpool, whose supervisors are Prof. Chi-Chang Hu (Department of Chemical Engineering, NTHU) and Prof. Laurence Hardwick (Department of Chemistry, UoL).

A major breakthrough related to Ca-air batteries

Prof. Hu said conventional lithium-ion batteries have a limited practical capacity. Thereby many researchers are working on developing alternative battery technologies. Their focus is on metal-air batteries based on zinc, lithium, sodium, potassium, calcium, magnesium, and aluminum. The advantage of the calcium-air battery is its high specific energy—five times that of traditional lithium-ion batteries. However, the feasibility of calcium-air batteries remains hampered by one major drawback—it cannot be recharged.

Lu explained that metal-air batteries are electrochemical cells usually using an active metal as the negative electrode, and a porous carbon material in contact with the air as the positive electrode. When the metal oxidized the oxygen at the positive electrode is reduced, generating electric current.

After completing his first year of doctoral studies at NTHU, Lu enrolled at the Stephenson Institute for Renewable Energy at UoL in September 2018. Under the supervision of Prof. Hardwick, he began doing research on the electrolyte used in calcium-air batteries.

Lu found when a single electrode is repeatedly charged and discharged, initially no reversibility can be observed, but after a few dozen cycles it gradually displays some reversibility. Surprisingly, the result seemed completely different from those in literature. The research team conducted a series of experiments aimed at uncovering the mechanism behind this phenomenon. On the electrode surface, the discharge products form a calcium oxide (CaxOy) interlayer, where the discharge product of oxygen, known as superoxide, is confined, allowing the superoxide to be then readily oxidized. This suggests the oxygen could probably be repeatedly oxidized/reduced, so that the cell can be continuously discharged/recharged.

Dr. Alex Neale, a Liverpool postdoctoral researcher, who is also part of the research team, said that through systematic electrochemical and spectroscopy investigations, the team began to understand the origins of this charge storage mechanism that facilitates a previously unseen degree of reversibility for systems based on the calcium-air battery.

Prof. Hardwick said the team will focus on designing new battery systems that use this newly discovered charge storage mechanism. He added that it was the cooperative research that made their discovery possible, and there are plans for even closer cooperation between NTHU and UoL in the future.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Holly Hsueh
NTHU
(886)3-5162006
hoyu@mx.nthu.edu.tw

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Teledyne FLIR Defense Launches Black Recon™ Autonomous Micro-Drone15.6.2026 07:05:00 EEST | Press release

Teledyne FLIR Defense, part of Teledyne Technologies Incorporated (NYSE: TDY), today announced at Eurosatory the market launch of Black Recon™, an autonomously launched micro-drone system that delivers continuous, untethered reconnaissance from military vehicles and fixed installations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260614388428/en/ Teledyne FLIR Defense announced at Eurosatory the market launch of Black Recon™, an autonomously launched micro-drone that delivers continuous, untethered reconnaissance from military vehicles and fixed installations. Black Recon allows crews to launch, operate, recover, and recharge up to three UAS without leaving their platform, reducing operator risk. Designed for vehicle integration, Black Recon allows crews to launch, operate, recover, and recharge up to three unmanned aerial systems without leaving their platform, reducing risk and accelerating decision-making. “Black Recon

OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 202614.6.2026 11:00:00 EEST | Press release

OM Pharma will reveal preliminary results from the REACH study at the European Academy of Allergy and Clinical Immunology (EAACI) Congress. REACH is the first and largest multi-country real-world evidence (RWE) study to date evaluating the impact of Broncho-Vaxom® in patients with recurrent respiratory tract infections (RTIs).1,2 The findings offer critical new clinical evidence of the therapy's effectiveness in everyday clinical practice. In a real-world cohort of 15,794 paediatric (aged >1 year), adolescent, adult and elderly patients in China, Italy, and Belgium, Broncho-Vaxom® was associated with reductions in RTI recurrence and healthcare utilisation at 12 and 24 months after treatment initiation, compared with the 12 months prior to starting the therapy.1 “The REACH real-world evidence study shows that Broncho-Vaxom® can significantly reduce infections requiring medical visits across age groups and co-morbidities,” said Anna Thomas, Chief Scientific Officer at OM Pharma. “Recurre

Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia13.6.2026 18:15:00 EEST | Press release

Incyte (Nasdaq:INCY) today announced updated clinical data from two Phase 1 studies evaluating the safety, tolerability and efficacy of INCA033989, a first-in-class mutant calreticulin (mutCALR)-targeted monoclonal antibody, in patients with mutCALR-expressing myeloproliferative neoplasms (MPNs). INCA033989 demonstrated rapid, clinically meaningful responses and consistent molecular activity across both myelofibrosis (MF) and essential thrombocythemia (ET), with convergent evidence supporting the potential for disease modification. These findings are being presented in oral and poster presentations at the European Hematology Association (EHA) 2026 Congress in Stockholm, Sweden (Session: Myeloproliferative neoplasms – Clinical, Presentation numbers: S216, PS1983, PF884). “The data presented at EHA 2026 demonstrate clinically meaningful and consistent responses with INCA033989 across both myelofibrosis and essential thrombocythemia,” said Pablo J. Cagnoni, M.D., President of Incyte and G

Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi ® /Minjuvi ® ) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival13.6.2026 13:00:00 EEST | Press release

Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified cytolytic CD19-targeting monoclonal antibody, and lenalidomide added to R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone; Tafa-Len-R-CHOP) versus R-CHOP, the current standard of care, as a first-line treatment for adults with previously untreated diffuse large B-cell lymphoma (DLBCL) or high-grade B-cell lymphoma (HGBL). Eligible patients had an International Prognostic Index (IPI) score of 3-5, or, for patients ≤60 years of age, an age-adjusted IPI (aaIPI) of 2-3. These data are being highlighted in a prestigious Plenary Abstracts Session at the European Hematology Association (EHA) 2026 Congress, being held June 11 - 14, 2026, in Stockholm, Sweden (Abstract # S101. Plenary Abstract Session. June 13, 6:00 - 7:30 a.m. ET [12:00-1:30 p.m. CEST]). frontMIND results were als

Charlotte Tilbury awarded CBE in the King’s Birthday Honours 202613.6.2026 00:31:00 EEST | Press release

Charlotte Tilbury CBE, sole Founder, President, Chairman and Chief Creative Officer of Charlotte Tilbury Beauty, has been awarded a Commander of the Order of the British Empire (CBE) in the King’s Birthday Honours 2026 for services to the beauty and cosmetics industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612679101/en/ Charlotte Tilbury, founder, president, chairman and chief creative officer of Charlotte Tilbury Beauty, who has been awarded a CBE (Commander of the Order of the British Empire) in 2026 for services to the beauty industry and entrepreneurship. (Photo: Charlotte Tilbury team) This honour recognises Charlotte’s contribution to leading and building Britain’s most successful global beauty brand. She has played a defining role in revolutionising the beauty industry and driving economic growth of the UK beauty sector, which has expanded from approximately £17bn in 2013 to over £31bn today. Charlotte Til

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye